HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

Impact · against what's priced in

HALO shares are likely to see an upward catalyst due to a new $1 billion share repurchase program and expanded royalty pipelines that exceed previous targets. While Q1 growth and guidance reiteration are expected, the scale of the buyback and new collaborations with GSK and Vertex provide fresh valuation support.

HALO+0.70

No priced-in read yet